

### Personal Information



## Shigetoyo Saji

Country: Japan

### Curriculum Vitae

#### BUSINESS ADDRESS :

1. Emeritus Professor of Gifu University ( <http://hosp.gifu-u.ac.jp/> )
2. Past President of Japanese Foundation for Multidisciplinary Treatment of Cancer ( <http://www.jfmc.or.jp/> )
3. Director of Japan Hospice Palliative Care Foundation ( <http://www.hospat.org/> )
4. Department of Surgery, Kizawa Memorial Hospital ( <http://kizawa-memorial-hospital.jp/> )

#### HOME ADDRESS :

62-1 Dousan-Cho, Gifu 502-0816 Japan,  
Phone & FAX : 81- 58-232-7178  
E-mail : [s.saji@iris.ocn.ne.jp](mailto:s.saji@iris.ocn.ne.jp)

#### EDUCATION :

M.D. : Gifu Prefectural Collage of Medicine 1964  
Ph.D.: Graduate School, Gifu University School of Medicine 1971  
Thesis : Medical Doctor ; Studies on life preservation of brain tissues under interrupted blood circulation.

#### POSTGRADUATE EDUCATION AND ACADEMIC POSITION :

Internship; Ohogaki City Hospital	1964 - 1965
Assistant; 2nd Department of Surgery Gifu University	1965 - 1974
Chairman; Department of Surgery, Gihoku Hospital	1974 - 1976
Assistant; 2nd Department of Surgery Gifu University	1976 - 1980
Professor and Chairman; 2nd Department of Surgery	1988 - 2001
Professor and Chairman, Dept of Tumor and General Surgery	2002 - 2003
Director of Gifu University Hospital	1998 - 2002
Emeritus Professor of Gifu University	2003-

#### Others:

Visiting Scientist supported by the Japanese Government Ministry of Education at Roswell  
Park Cancer Institute, NY, U.S.A. : 1982-1983  
City of Hope National Medical Center, CA, U.S.A. : 1983-1983  
Scientist at Roswell Park Cancer Institute, NY, U.S.A. : 1984 - 1985

#### **MEMBERSHIP IN SCIENTIFIC SOCIETIES:**

Japan Surgical Society (Meritorious Member),  
Japanese Society of Gastroenterological Surgery (Honorary Member)  
Japan Society of Clinical Oncology (Honorary Member)  
Japan Society for Biological Therapy (Honorary Member)  
Japanese Cancer Association (Meritorious Member)  
Japanese Gastric Cancer Association (Meritorious Member)  
Japanese College of Surgeons (Meritorious Member, Fellow)  
Japan Society for Low Temperature Medicine (Honorary Member)  
et al, total about over 30 societies.

#### **EDITORIAL BOARD :**

Journal of Clinical Cancer Research  
Current Oncology,  
Advances in Therapy  
Journal of Japanese Society of Gastroenterological Surgery (past chief editor)  
Surgery Today (Journal of Japan Surgical Society)  
Biotherapy  
Journal of Japanese College of Surgeons

#### **PRESIDENT OF ANNUAL MEETIG:**

The 8<sup>th</sup> Annual Meeting of Japan Society for Biological Therapy (1995)  
The 18<sup>th</sup> Annual Meeting of Cancer Immuno-Surgery (1997)  
The 37<sup>th</sup> Annual Meeting of Japan Society of Clinical Oncology (1999)  
The 21<sup>th</sup> Annual Meeting of Japanese Society for Research of Loco-Regional Cancer Therapy  
(1999)  
The 31<sup>th</sup> Annual Meeting of Japanese Society for Cancer and Lymph Node Research (1999)  
The 7<sup>th</sup> Annual Meeting of Surgical Stress and Cytokine Research (2000)  
The 38<sup>th</sup> Annual Meeting of Chubu Surgical Society (2002)  
The 29<sup>th</sup> Annual Meeting of Japan Society of Low Temperature Medicine (2002)  
The 9<sup>th</sup> International Conference of the Asian Clinical Oncology Society (2010) :  
<http://www.acos2010.org/>

#### **RESEARCH INTERESTS:**

Gastroenterological surgery (Operative procedure, Quality of life)  
Surgical oncology (Pre- and post-operative chemotherapy, Drug sensitivity test)  
Cancer immunology and immunotherapy (Cell therapy, Host immuno-competency)  
Gene characteristics and Gene diagnosis for cancer of the digestive organ, breast cancer, etc.

## PUBLICATIONS AND REFEREED JOURNALS:

(Recent English references from 2000, Total 18 books, 964 references since 1968)

- 1) Ohno R, et al: A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 its biological effects in Japanese patients with advanced malignancies. *Clin Cancer Res* 6:2661-2669, 2000
- 2) Takagi Y, et al: Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers. *GUT* 47:268-271, 2000.
- 3) Yamaguchi K, et al: Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. *Ann Surg* 232:58-65, 2000.
- 4) Takahashi T, et al: Centrosomal kinase, HsAIRK1 and HsAIRK3, are over expressed in primary colorectal cancers, *Jpn J Cancer Res* 91:1007-1014, 2000.
- 5) Osada S, et al: Critical role of extracellular signal-regulated kinase (ERK) phosphorylation in novel Vitamin K analog-induced cell death. *Jpn J Cancer Res* 91:1250-1257, 2000.
- 6) Okumura N, et al: Distinct promoter usage of mdm2 gene in human breast cancer, *Oncology Reports* 9:557-563, 2002
- 7) Kuno T, et al: Induction of apoptosis by sulindac in azoxymethane-induced possible colonic premalignant lesions in rats. *Jpn J Cancer Res* 93:242-246, 2002
- 8) Aoki S, et al: Detection of peritoneal micrometastases by reverse transcriptase-polymerase chain reaction targeting carcinoembryonic antigen and cytokeratin 20 in colon cancer patients. *J Exp Clin Cancer Res* 21:555-562, 2002
- 9) Matsushashi N et al : Expression of p53 protein as a predictor of the response to 5-fluorouracil and cisplatin chemotherapy in human gastrointestinal cancer cell lines evaluated with apoptosis by use of thin layer collagen gel. *International Journal of Oncology* 24:807-813, 2004.
- 10) Osada S, et al : Clinical significance of combination study of apoptotic factor and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma. *J Surg Oncology* 85:48-54, 2004.
- 11) Matsushashi N, et al : Apoptosis induced by 5-fluorouracil, cisplatin and paclitaxel are associated with p53 gene status in gastric cancer cell lines. *International Journal of Oncology* 24:1563-1567, 2005.
- 12) Saji S, et al: Recent advances of cancer in Asian countries . *Cancer and Chemotherapy Publishers Co. Japan, Tokyo, p75, 2010.*
- 13) Toi M, et al: Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. *Cancer Science* 2011 : 858-865, Article first published online: 2011:1349-7006,
- 14) Nakata B, et al.: Phase II Trial of S-1 plus Low-Dose Cisplatin for Unresectable and Recurrent Gastric Cancer (JFMC27-9902 Step2). *Oncology*. 2010;79(5-6):337-42.

- 15) Shimada M, et al: Effect of TU-100, a traditional Japanese medicine, administered after hepatic resection in patients with liver cancer: a multi-center, phase III trial (JFMC40-1001). *Int J Clin Oncol.* 2014(3)
- 16) Matsusaka S, et al. : Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).*Gastric Cancer.* 2015(8)
- 17) Matsusaka S, et al. : Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).*Gastric Cancer.* 2015 Aug 12.
- 18) Kusano M, et al.:A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32). *J Can Res Ther.* 2016 Mar.
- 19) Suto T, et al : Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer..*Int J Clin Oncol.* 2017 Jun 12.
- 20) Tanaka H, et al : Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003). *Int J Clin Oncol.* 2017 Jun 30.